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The therapeutic efficacy of anthracyclines relies on
antitumor immune responses elicited by dying can-
cer cells. How chemotherapy-induced cell death
leads to efficient antigen presentation to T cells,
however, remains a conundrum. We found that intra-
tumoral CD11c+CD11b+Ly6Chi cells, which displayed
some characteristics of inflammatory dendritic cells
and included granulomonocytic precursors, were
crucial for anthracycline-induced anticancer immune
responses. ATP released by dying cancer cells re-
cruited myeloid cells into tumors and stimulated the
local differentiation of CD11c+CD11b+Ly6Chi cells.
Such cells efficiently engulfed tumor antigens
in situ and presented them to T lymphocytes, thus
vaccinating mice, upon adoptive transfer, against a
challenge with cancer cells. Manipulations prevent-
ing tumor infiltration by CD11c+CD11b+Ly6Chi
cells, such as the local overexpression of ectonu-
cleotidases, the blockade of purinergic receptors,
or the neutralization of CD11b, abolished theimmune system-dependent antitumor activity of
anthracyclines. Our results identify a subset of
tumor-infiltrating leukocytes as therapy-relevant
antigen-presenting cells.
INTRODUCTION
Although it has been generally believed that cytotoxic antineo-
plastic agents mediate their therapeutic effects in a cancer
cell-autonomous fashion, at least some chemotherapeutics
inhibit tumor growth also indirectly, via the immune system (Mell-
man et al., 2011; Schreiber et al., 2011). Thus, a variety of trans-
plantable or chemically induced primary mouse cancers
respond more efficiently to anthracyclines when they develop
in hosts carrying an intact immune system. In many cases,
tumors evolving in immunodeficient mice fail to respond to
anthracyclines in conditions in which the same tumors growing
in immunocompetent mice do so (Apetoh et al., 2007; Casares
et al., 2005; Ghiringhelli et al., 2009; Michaud et al., 2011).
Accordingly, clinical studies indicate that anthracycline-killed
tumor cells are particularly efficient in stimulating a therapeutic
immune response in cancer patients (Zappasodi et al., 2010).
Moreover, anthracycline-based neoadjuvant therapy of breastImmunity 38, 729–741, April 18, 2013 ª2013 Elsevier Inc. 729
Immunity
Antigen-Presenting Cells in Anthracycline Therapycancer patients is more effective when the tumor is infiltrated by
T cells before the beginning of chemotherapy (Denkert et al.,
2010) as well as if chemotherapy causes a significant influx of
CD8+ T cells into the tumor bed and/or reduces the accumulation
of immunosuppressive regulatory T (Treg) cells (Ladoire et al.,
2011).
Several immune effectors that are essential for the therapeutic
effect of anthracyclines have been characterized in mouse
models. Indeed, the deletion of genes coding for several cyto-
kines (Il1b, Il17a, Ifng) or their receptors (Il1r, Il17r, Ifngr) abol-
ishes the anticancer effects of anthracyclines, and so does the
injection of antibodies that neutralize IL-1b, IL-17, and IFN-g or
that deplete CD4+, CD8+, and gd T cells (Ghiringhelli et al.,
2009; Ma et al., 2011; Michaud et al., 2011; Obeid et al., 2007).
Functional experiments suggest a hierarchy of events whereby
IL-1b produced by dendritic cells (DCs) allows for the activation
of IL-17A-producing gd T cells, which eventually sustain the
accumulation of IFN-g-producing CD8+ T cells into the tumor
bed, 1 week after the chemotherapy has started (Ma et al., 2011).
In contrast to most other cytotoxic chemotherapeutics,
anthracyclines stimulate immunogenic cell death. This type of
cell death is characterized by a compendium of subtle biochem-
ical changes in the properties of the plasmamembrane aswell as
in the microenvironment of dying cancer cells (Galluzzi et al.,
2012; Green et al., 2009). These changes include the preapop-
totic exposure of calreticulin (CRT) on the cell surface (which
facilitates the engulfment of portions of the dying cells by anti-
gen-presenting cells, APCs) (Gardai et al., 2005) and the posta-
poptotic release of high mobility group box 1 (HMGB1) from the
nucleus (which binds TLR4 receptors and hence stimulates anti-
gen presentation) (Apetoh et al., 2007). We have found that the
release of ATP by dying tumor cells is also essential for cell death
to be perceived as immunogenic. Indeed, ATP stimulates the
recruitment of inflammatory cells into the tumor bed and binds
P2RX7 receptors on DCs, thereby facilitating the activation of
the NLRP3 inflammasome and the consequent secretion of
IL-1b (Ghiringhelli et al., 2009; Martins et al., 2009). Neoplasms
in which the pathways leading to CRT exposure or ATP release
have been interrupted are refractory to anthracyclines in vivo
(Michaud et al., 2011; Panaretakis et al., 2009). Along similar
lines, the elimination of TLR4 or P2RX7—as well as that of
their intracellular signal transducers MYD88, NLRP3, and
caspase-1—from the host immune system is detrimental for
the efficacy of anthracycline-based chemotherapy (Ghiringhelli
et al., 2009; Obeid et al., 2007).
An abundant literature has described different DC subsets
that would be endowed with the capacity to capture dead cell-
associated antigens and to stimulate or subvert anticancer
immune responses in vivo (Mellman et al., 2011; Palucka and
Banchereau, 2012). Beyond plasmacytoid DCs (pDCs), which
are mostly tolerogenic (Matta et al., 2010), conventional DCs
(cDCs) have been subclassified into inflammatory and BATF3-
dependent DCs. The former exhibit a CD11c+CD11b+Ly6C+
surface phenotype and play an important role in CD4+ T cell
and antimicrobial responses (Kool et al., 2008). The latter ex-
press CD8a and/or CD103 and are particularly efficient at engulf-
ing and cross-presenting antigens from dead cells to CD8+ T
lymphocytes (Albert et al., 1998; Hildner et al., 2008). The differ-
entiation requirements and functional properties of these DC730 Immunity 38, 729–741, April 18, 2013 ª2013 Elsevier Inc.subsets are highly heterogeneous, suggesting their specific
involvement in peculiar sets of immune responses (Mellman
et al., 2011; Palucka and Banchereau, 2012).
Here, we addressed the question as to how dead tumor cell
antigens are presented to T cells upon anthracycline treatment
in vivo. We observed that anthracycline-based chemotherapy
stimulates the ATP-driven and purinergic receptor-dependent
accumulation of CD11c+CD11b+Ly6Chi tumor-infiltrating leuko-
cytes (TILs). This subset of TILs appeared particularly efficient
at presenting tumor antigens to CD8+ T cells in vitro and in vivo.
Accordingly, experimental manipulations that suppress the
recruitment of CD11c+CD11b+Ly6Chi cells into the tumor bed,
such as the enzymatic degradation of local ATP, the pharmaco-
logical inhibition of purinergic receptors, and the injection of
CD11b-neutralizing antibodies, all abolished the therapeutic
effects of anthracyclines. Our results support the notion that
CD11c+CD11b+Ly6Chi TILs are essential for the efficacy of
anthracycline-based chemotherapy.
RESULTS
Chemotherapy-Induced Recruitment of Myeloid
Cells into the Tumor Bed
When murine MCA205 fibrosarcomas growing in syngenic
C57Bl/6 mice reached a diameter of 5–10 mm, they contained
<1% cells with the surface phenotype of mature DCs (CD11c+
CD86+), macrophages (F4/80+CD169+), and granulocytes
(CD11b+Ly6G+) and <10% of cells bearing the general myeloid
marker CD11b, as detectable by in situ immunofluorescence
and confocal microscopy. Systemic chemotherapy with the
prototypic anthracycline mitoxantrone (MTX) led to a rapid
(12 hr) increase in the prevalence of CD11c+CD86+ cells, fol-
lowed by a slightly delayed (48 hr) accumulation of F4/
80+CD169+ and CD11b+Ly6G+ TILs (Figures 1A and 1B). These
three cell types were localized in the immediate proximity of
dying tumor cells, as shown by the distance to the closest cancer
cell positive for cleaved caspase-3 (a marker of apoptosis),
which was significantly shorter than that to the closest living
cancer cell (Figures 1C and 1D). As previously reported (Chow
et al., 2011), CD11c+CD86+ cells were significantly more elon-
gated than F4/80+CD169+ and CD11b+Ly6G+ TILs, whereas
both CD11c+CD86+ and F4/80+CD169+ cells were larger than
CD11b+Ly6G+ cells (Figure 1C). Mechanic and enzymatic
dissociation of tumors followed by immunofluorescence and
cytofluorometric analyses confirmed the recruitment of myeloid
(CD45+CD11b+) cells, and more specifically DCs (CD11c+MHC-
II+), bearing monocytic markers (Ly6C+7/4+), but not of other cell
types such as Treg cells (CD3+CD4+FOXP3+) or Th17 cells
(CD3+CD4+IL-17+), into the tumor bed 2 days after chemo-
therapy with doxorubicin (DX, another widely employed anthra-
cycline), correlating with the induction of cancer cell death
(Figures 1E and 1F; Figure S1 available online; data not shown).
Altogether, these results indicate that distinct classes of myeloid
cells accumulate in the tumor bed after chemotherapy.
Critical Involvement of ATP and Purinergic Receptors
in the Recruitment of Myeloid Cells
To elucidate the mechanisms accounting for the chemotherapy-
induced recruitment of myeloid cells into the tumor bed, we
Figure 1. Chemotherapy Induces the Accu-
mulation of Myeloid Cells in Close Proximity
to Dying Cells
Wild-type C57BL/6 mice bearing MCA205 fibro-
sarcomas were treated with mitoxantrone (MTX)
i.p. (A–D), doxorubicin (DX) i.t. (E, F), or with an
equivalent volume of PBS, as a single injection. At
the indicated time points (48 hr where not indi-
cated), tumors were harvested and processed for
the detection of the indicated proteins by immu-
nofluorescence microscopy (A–D) or for cyto-
fluorometric determinations (E, F). Hoechst 33342
was employed as nuclear counterstaining.
(A) Representative images (scale bars represent
25 mm).
(B) Quantitative data on the frequency of the
indicated cell populations (means ± SEM, in 10
viewfields for at least n = 10 distinct tumors).
(C) The indicated myeloid cell populations were
quantitatively characterized for their intercellular
distance from tumor cells displaying (+) or not ()
activated caspase 3 (Casp3a) (left), cell surface
(middle), and the length/width ratio (right), as
determined by morphometric methods. Boxplots
report the lower and upper quartile plus the me-
dian value. Whiskers indicate min and max values.
(D) A CD11c+CD86+ dendritic cell (DC) in the close
proximity of a dying tumor cell (scale bars repre-
sent 10 mm).
(E) Representative dot plots of cells from PBS-
treated and DX-treated tumors are depicted,
including dead cells that incorporate the exclusion
dye vivid yellow and living CD11b+CD45+ tumor-
infiltrating leucocytes. Numbers indicate the
percentage of cells foundwithin the corresponding
gate.
(F) The corresponding quantitative data (means ±
SEM).
*p < 0.05, **p < 0.01, ***p < 0.001 (unpaired, two-
tailed Student’s t test). See also Figure S1.
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express the ecto-ATPase CD39 on the cell surface (Michaud
et al., 2011; Stagg and Smyth, 2010). In response to MTX-
based chemotherapy, CD39+ MCA205 tumors failed to attract
CD11c+CD86+, F4/80+CD169+, or CD11b+Ly6G+ cells, whereas
control tumors (derived from MCA205 cells transduced with an
empty vector) did so (Figure 2A), indicating that ATP is essential
for the recruitment of these myeloid cells in the tumor bed. Tu-
mors developing in mice that lack the metabotropic purinergic
receptor P2Y2 (which mediates the chemotaxis of monocytes
toward apoptotic cells) (Chekeni et al., 2010; Elliott et al., 2009)
also failed to accumulate CD11c+CD86+, F4/80+CD169+, andImmunity 38, 729–7CD11b+Ly6G+ cells after the administra-
tion of MTX (Figure 2B). Suramin, a
nontoxic broad-spectrum inhibitor of
purinergic receptors (Elliott et al., 2009),
prevented the recruitment of both
CD11c+CD86+ and CD11b+Ly6G+ cells
yet failed to affect the frequency, polari-
zation, and function of F4/80+CD169+
macrophages (Figures 2C and S2). Thelocal overexpression of CD39 (Figure 2D) and the administration
of suramin (Figure 2E) abolished the growth-inhibitory effects of
systemic MTX-based chemotherapy in a similar fashion, under-
scoring the functional importance of ATP and purinergic recep-
tors for the therapeutic efficacy of anthracyclines.
Identification of APCs among Tumor-Infiltrating
Myeloid Cells
The ablation of tumor-draining lymph nodes shortly after chemo-
therapy or even before tumor implantation failed to reduce the
efficacy of anthracycline-based chemotherapy (Figure S3A).
Similar results were obtained upon the injection of a lymphotoxin41, April 18, 2013 ª2013 Elsevier Inc. 731
Figure 2. Obligate Contribution of ATP and
Purinergic Receptors to Anthracycline-
Induced Accumulation of Myeloid Cells
and Chemotherapeutic Outcome
(A–C)Wild-type (WT) (A–C) orP2y2/ (B) C57BL/6
mice bearing WT (A–C) or CD39-expressing
(CD39) (B) MCA205 fibrosarcomas received mi-
toxantrone (MTX) i.p. or an equivalent volume of
PBS, either alone (A–C) or combined with sur-
amine i.v. (C), and tumor-infiltrating leucocytes of
the indicated phenotypes were quantified 48 hr
later by immunofluorescence microscopy. Quan-
titative data are represented as means ± SEM;
*p < 0.05, **p < 0.01, ***p < 0.001; ns, nonsignifi-
cant (unpaired, two-tailed Student’s t test).
(D and E) WT C57BL/6 mice were inoculated s.c.
with WT (D, E) or CD39 (D) MCA205 cells and
tumor size was routinely assessed. When tumor
became palpable (surface area = 25 mm2), mice
received MTX i.p. or an equivalent volume of PBS,
either alone (D, E) or combined with suramine i.v.
(E). Quantitative data are represented as means ±
SEM; *p < 0.05 (Mann-Whitney U test).
See also Figure S2.
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LTb (Figure S3B), as well as after the simultaneous neutralization
of IL-7 and IL-7R (Figure S3C), two measures that abolish the
formation of tertiary lymphoid structures (Gra¨bner et al., 2009;
Meier et al., 2007). Moreover, anthracycline-based chemo-
therapy failed to enhance (and actually it reduced) the number
of TILs exhibiting the surface phenotype of lymphoid tissue in-
ducers (CD45+B220CD11cCD3CD4+CD127+) (Figure S3D),
yet led to the activation of tumor-infiltrating CD8+ T cells and
adoptively transferred ovalbumin (OVA)-specific OT-I cells732 Immunity 38, 729–741, April 18, 2013 ª2013 Elsevier Inc.against OVA-expressing MCA205 tumors
from within the tumor bed (Figure S3E). In
this model, the proliferation of intratu-
moral OT-I cells induced by chemo-
therapy was not reduced by the surgical
removal of draining lymph nodes. More-
over, chemotherapy did not increase
the frequency of CD11c+MHC-II+ cells
detectable in tumor-draining lymph no-
des (data not shown). Altogether, these
results suggest that the presentation of
tumor antigens relevant to the success
of anticancer chemotherapies may take
place in the tumor bed itself, even in the
absence of draining lymph nodes and
tertiary lymphoid structures.
To determine the origin of intratumoral
DCs (CD11c+MHC-II+ cells), we estab-
lished MCA205 cancers in CD45.1 mice,
treated themby vehicle or chemotherapy,
transplanted them 1 day later to
isogenic CD45.2 C57BL/6 recipients,
and measured the frequency of tumor-
sessile (CD45.1+) versus freshly recruited
(CD45.2+) DCs. The ratio of recipient-derived (CD45.2+) versus donor-derived (CD45.1+) CD11c+
MHC-II+ DCs was increased by chemotherapy, supporting the
notion that chemotherapy triggers the recruitment of DC precur-
sors rather than a mere in situ differentiation of pre-existing
myeloid cells (data not shown). To characterize the intratumoral
APCs responsible for the chemotherapy-relevant presentation of
tumor antigens, we engineered mouse CT26 colon cancers cells
to express EGFP on the inner leaflet of the plasma membrane
owing to the addition of a myristoylation motif (Figure 3A).
Upon the administration of DX, a significant fraction of CD45+
Immunity
Antigen-Presenting Cells in Anthracycline TherapyTILs, especially among the CD11b+Ly6ChiLy6G subset,
became positive for EGFP (Figure 3B). In this context, CD11b+
Ly6ChiLy6G cells exhibited a stronger EGFP positivity and
higher expression of CD11c than did CD11b+Ly6CloLy6G cells
and CD11b+Ly6G+ granulocytes. Moreover, CD11b+Ly6Chi
Ly6G cells clearly manifested the presence of EGFP in the cyto-
plasm, an indication of the uptake of antigens from tumor cells.
Of note, the frequency of CD11b+Ly6CloLy6G cells, which
also engulfed tumor antigens, did not increase in response to
chemotherapy (Figures 3C and 3D).
CD11b+Ly6ChiLy6G cells accumulated in the tumor bed after
chemotherapy in an ATP-dependent fashion (data not shown),
mostly exhibited DC markers (CD11c+MHC-IIintF4/80lo), and
stained positive for 7/4, CD103, CD172a, CCR2, and CX3CR1,
but lacked CD205 expression (Figure S4). When we treated
palpable OVA-expressing MCA205 fibrosarcomas
with anthracyclines, the frequency of Ly6ChiLy6G cells (as
determined upon the cytofluorometric purification of the
Ly6ChiLy6G, Ly6CloLy6G, and Ly6G+ subsets of CD11b+
TILs) increased, and these cells turned out to be particularly
efficient in stimulating the production of IFN-g by MHC class I-
restricted OVA-specific OT-I cells in vitro. Moreover,
Ly6ChiLy6G cells recovered from DX-treated OVA-expressing
tumors were much more efficient than their Ly6CloLy6G coun-
terparts as well as than Ly6G+ cells in stimulating the secretion of
IL-2 by MHC class I-restricted OVA-specific B3Z hybridomas
(Figure 3E). This effect was antigen specific (as shown by the
fact that Ly6ChiLy6G cells recovered from OVA-negative
tumors failed to stimulate B3Z cells) and required MHC mole-
cules. Ly6ChiLy6G TILs recovered from homozygous
H2KbDb-deficient hosts (Pe´rarnau et al., 1999) failed indeed to
elicit IL-2 production by B3Z cells. Noteworthy, tumor or stromal
cells (namely, the CD45 cell subset harvested from anthracy-
cline-treated OVA-expressing MCA205 tumors) failed to directly
activate OT-I or B3Z ex vivo (Figure 3E).
Next, we purified Ly6ChiLy6G, Ly6CloLy6G, and Ly6G+ TILs
(all sharing the surface phenotype CD45+B220CD3CD11b+)
from vehicle-treated or DX-treated OVA-expressing MCA205
tumors and adoptively transferred them into naive mice that
were challenged 10 days later with living OVA-expressing
MCA205 cells. Importantly, only Ly6ChiLy6G (but neither
Ly6CloLy6G nor Ly6G+) TILs harvested from anthracycline-
treated tumors were capable of reducing the incidence and
growth of tumors (Figure 3F), indicating that this population
indeed contains functionally competent APCs. Accordingly,
purified Ly6ChiLy6G TILs exhibited a significant increase
in the expression of genes relevant to MHC class I- or II-
restricted antigen presentation after DX-based chemotherapy,
in vivo (data not shown). Altogether, these results identify
CD11b+Ly6ChiLy6G TILs as the cells that accumulate in the
tumor bed to exert APC functions in response to anthracycline
treatment.
ATP-Dependent Differentiation of Myeloid Precursors
into Dendritic Cells
Chemotherapy with anthracyclines induced the accumulation
of CD34+c-Kit+Sca-1+CD11bintCD16/32+/ multipotent progeni-
tors (MPPs) and CD34+c-Kit+Sca-1CD11bintCD16/32hi/lo
myeloid precursors (MPs) in tumors (data not shown). A moredetailed characterization of myeloid TILs (CD45+B220
CD3CD11b+) revealed that several cell subsets, including
Ly6ChiLy6G, Ly6CloLy6G, and Ly6G+ cells, contained a signif-
icant fraction of cells exhibiting a common myeloid progenitor
(CMP) or granulocyte-monocyte progenitor (GMP) phenotype
(CD34+c-Kit+Sca-1CD16/32+), and more so after chemo-
therapy. Of note, the frequency of such CMP or GMP-like cells
among Ly6ChiLy6G TILs was reduced by the presence of the
ecto-ATPase CD39 on the surface of tumor cells (Figure 4A).
Quantitative RT-PCR analyses confirmed that transcription
factors and regulators associated with the monocytic lineage
(i.e., PU.1, Nab2) (Auffray et al., 2009; Laslo et al., 2006) were
upregulated, in particular among Ly6ChiLy6G TILs, after DX-
based chemotherapy, and that this increase was abolished by
the expression of CD39 (Figure 4B). The expression of transcrip-
tion factors relevant for the differentiation of granulocytes (i.e.,
Gfi1) (de la Luz Sierra et al., 2010; Laslo et al., 2006) or the mega-
karyocytic-erythrocytic lineage (i.e., Gfi1b and Gata1) (Yu et al.,
2009) was increased in response to DX, yet predominantly
among Ly6G+ cells and independently of CD39 (Figure 4B). In
line with these observations, Ly6ChiLy6G (but not Ly6G+) TILs
recovered from tumors and propagated in dedicated methylcel-
lulose cloning conditions could form colonies that were highly
proliferative (Figures 4C–4E). These proliferating cells retained
GMP markers and acquired the morphology and phenotype of
monocytes (Figure 4F and data not shown). Anthracycline-based
chemotherapy dramatically increased the frequency of colony-
forming units among Ly6ChiLy6G TILs, an effect that was pre-
cluded by the expression of CD39 by tumor cells (Figure 4C).
Thus, chemotherapy appears to induce the recruitment of
GMPs with monocytic differentiation potential at the tumor site,
in an ATP-dependent manner.
Chemotherapy Induced the ATP-Dependent
Differentiation of CD11b+Ly6Chi Tumor-Infiltrating
Leucocytes into Inflammatory DC-like Cells
We characterized the impact of the intratumoral milieu on the dif-
ferentiation of Ly6ChiLy6G TILs into bona fide DCs, placing
special emphasis on ATP. Ly6ChiLy6G TILs were recovered
from tumors established in CD45.2 C57BL/6 mice and treated
with anthracyclines and then adoptively transferred into
MCA205 tumors growing in congenic CD45.1 mice that were
treated with either vehicle (PBS) or DX. Upon transfer into tumors
that did not receive chemotherapy, the initial CD45.2+Ly6Chi
Ly6G cell population mostly differentiated into CD45.2+Ly6G+
granulocytes. In contrast, upon transfer into anthracycline-
treated tumors, a fraction of Ly6ChiLy6G TILs maintained the
Ly6ChiLy6G phenotype and acquired surface markers of DCs
(namely CD11c and MHC class II molecules) (Figures 5A–5C).
Similar results were obtained in a syngeneic (CD45.2) system
in which Ly6ChiLy6G or Ly6G+ TILs recovered from anthracy-
cline-treated tumors were labeled with CFSE and then trans-
ferred into anthracycline-treated MCA205 tumors. A substantial
fraction of such Ly6ChiLy6GCFSE+ cells acquired the expres-
sion of CD11c and CD86 (Figures 5D and 5E). Failure to provide
chemotherapy as well as transfer into CD39-expressing tumors
reduced the frequency of the adoptively transferred cells that
could be recovered from the tumor bed (Figures 5E and 5F). As
a control, the Ly6G+ population, which did not contain significantImmunity 38, 729–741, April 18, 2013 ª2013 Elsevier Inc. 733
Figure 3. Chemotherapy Promotes the Uptake and Presentation of Tumor Antigens by CD11c+Ly6ChiLy6G– Tumor-Infiltrating Leucocytes
(A–D)BALB/cmicebearingMyrPalm-EGFP-expressingCT26 tumorswere treatedwithdoxorubicin (DX) i.t. orwithanequivalent volumeofPBS.At the indicated time
points (38 hr, where not indicated), tumors were harvested and processed for immunofluorescence studies (A and C) or cytofluorometric determinations (B and D).
(A) MyrPalm-mEGFP-expressing mouse colon carcinoma CT26 cells, exhibiting a plasma membrane-restricted distribution of EGFP (scale bar represents
7.5 mm).
(B) Representative dot plots of EGFP+CD45+ tumor-infiltrating leucocytes (TILs) stained for CD11b, Ly6C, and Ly6G are illustrated on the left, and quantitative
data are reported on the right.
(C) Uptake of tumor antigens (as exemplified by EGFP) bymyeloid cells of the indicated phenotype (top, scale bar represents 2.5 mm) and quantitative kinetic data
(bottom).
(D) Representative cytofluorometric distribution of EGFP and CD11c mean fluorescence intensity for the indicated myeloid cell populations.
(A and C) Hoechst 33342 was employed as nuclear counterstaining.
(legend continued on next page)
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CD11c+CD86+ cells upon adoptive transfer into anthracycline-
treated tumors (Figure 5E). Altogether, these results suggest
that chemotherapy-elicited ATP release within the tumor bed
can skew the differentiation of CD11b+Ly6ChiLy6G TILs toward
a CD11c+ DC-like phenotype, hence subverting their default
pathway leading to the generation of Ly6G+ granulocytes, which
we observed within PBS-treated tumors (Figure 5C).
To get further insights into this issue, we cocultured control or
CD39+ MCA205 cells that were optionally treated with anthracy-
clines in vitro (CD39 expression abolished the anthracycline-
driven accumulation of extracellular ATP; Figure 5G) with bone
marrow-derived CD11b+Ly6ChiLy6G cells, a substantial part
(around 30%–40%) of which showed a GMP phenotype. Only
anthracycline-treated CD39 (but not CD39+) tumor cells stimu-
lated such a subset to express the monocyte-relevant transcrip-
tion factor PU.1 (Figure S5). Along similar lines, only CD39 cells
treated with anthracyclines (but neither anthracycline-treated
CD39+ cells nor untreated CD39 cells) enhanced the differenti-
ation of CD11b+Ly6ChiLy6G bone marrow cells into CD11b+
Ly6C+ monocytes (de facto limiting granulocytic differentiation)
and allowed for the generation of a significant number of
CD11c+MHC-II+ DC-like cells (Figures 5H and 5I). This skew in
differentiation from Ly6G+ granulocytes to cells with a CD11b+
CD11c+ DC phenotype was reduced by the pannexin 1 inhibitor
DIDS (which limits ATP release from dying cells) and by several
purinergic receptor antagonists including oxidized ATP and
suramin, but neither by recombinant IL-1 receptor antagonist
(IL-1RA) nor by the TNF-a antagonist etanercept (Figures 5J
and 5K). These results underscore the importance of extracel-
lular ATP and purinergic receptors for the generation of DCs in
response to anthracyclin-based chemotherapy.
Identification of the DC Subset Underlying
Chemotherapy-Induced Anticancer Immune Responses
Multiple distinct DC subsets might contribute to the presentation
of dead cell antigens to T cells. To identify the specific DC pop-
ulation that is relevant to anticancer chemotherapy, we first in-
jected a PDCA-1-specific antibody into tumor-bearing mice
that had received anthracyclin-based chemotherapy. Although
the PDCA-1-targeting antibody effectively depleted plasmacy-
toid DCs (data not shown), this treatment neither suppressed
the chemotherapy-induced accumulation of CD11b+CD11c
GFP+ TILs (in mice that express GFP under the control of the
CD11c promoter) (Figure 6A) nor reduced the efficacy of anthra-
cycline- and oxaliplatin-based chemotherapy (Figures 6B and
6C). Along similar lines, the deletion of the transcription factor
Batf3, which is essential for the generation of CD8a+CD103+
Langerin+ DCs (Hildner et al., 2008), failed to reduce MTX-(B and C) Quantitative data are represented as means ± SEM; *p < 0.05, **p < 0
(E) WT or H2KbDb/ C57BL/6 mice bearing OVA-expressing (OVA) MCA205
cytofluorometry 38 hr after chemotherapy upon staining with Ly6C- and Ly6G-sp
withOT-I cells for 72 hr or withOVA-specific T cell hybridomaB3Z cells for 36 hr an
(IL-2, right) levels. Numbers indicate the percentage of cells found within the corre
***p < 0.001 (unpaired, two-tailed Student’s t test).
(F) Alternatively, PBS (negative control) or myeloid cells sorted as in (E) from PBS-
WT C75BL/6 mice, which were rechallenged 10 days later with living OVA MCA
Results from one representative experiment out of three independent ones invol
See also Figure S3.induced tumor infiltration by CD11b+CD11c+ TILs (Figure 6D),
and tumors implanted in wild-type and Batf3/mice responded
to chemotherapy in an indistinguishable fashion (Figure 6E). In
contrast, the injection of a CD11b-blocking antibody strongly
reduced the frequency of CD11b+Ly6Chi cells in the peripheral
blood (Figure 6F), as well as of CD11b+CD11cGFP+ cells infil-
tratingMTX-treated tumors (Figure 6G). In accordwith the finding
that CD11b+CD11c+ TILs are responsible for chemotherapy-
relatedantigenpresentation andantitumorprotection in vivo (Fig-
ure 3), neutralization of CD11b abolished the anticancer effect of
anthracyclines in four different tumor models, namely MCA205
fibrosarcomas and AT3 mammary cancers, both of which grow
in C57BL/6 mice (Figures 6H and 6I), F244 sarcoma cells, which
form tumors in 129/Sv mice (Figure 6J), and H2N100 mammary
cancers, developing in BALB/c mice (Figure 6K). In contrast,
the depletion of macrophages (with clodronate-containing lipo-
somes) or neutrophils (with the1A8antibody) hadnooronlyminor
effects, respectively, on the efficacy of chemotherapy (Figure S6
and data not shown). Altogether, these results underscore the
fundamental importance of inflammatory DC-like CD11b+
CD11c+ cells for the efficacy of anticancer chemotherapy.
DISCUSSION
Our findings provide at least three lines of evidence indicating
that a peculiar subtype of TILs, namely CD11c+CD11b+Ly6Chi
cells, which share some of the characteristics of inflammatory
DCs (Cheong et al., 2010), is particularly important for the induc-
tion of anticancer immune responses by anthracyclines. First,
CD11c+CD11b+Ly6Chi cells were recruited into the tumor bed
as early as 12 hr after chemotherapy. Second, manipulations
aimed at preventing the intratumoral accumulation of such cells,
including (1) the local overexpression of the ATP-degrading
enzyme CD39, (2) the pharmacological blockade of purinergic
receptors, and (3) the neutralization of CD11b with a specific
antibody, abolished the immune-dependent anticancer effects
of anthracyclines. Third, functional experiments revealed that
CD11c+CD11b+Ly6Chi TILs are particularly efficient in capturing
and presenting tumor cell antigens and that such cells—once
adoptively transferred into naive mice—can confer protection
against a challenge with living tumor cells.
ATP appears to be particularly important for the infiltration of
myeloid TILs into the tumor bed upon anthracycline-based
chemotherapy. Indeed, palpable tumors generated from cancer
cells manipulated to overexpress the ecto-ATPase CD39 failed
to recruit TILs of various types, including cells with a DC-like,
macrophage-like, or granulocyte surface phenotype in response
to anthracyclines. In line with recent results (Chen et al., 2006),
P2Y2 turned out to be essential for the chemotherapy-induced.01, ***p < 0.001 (unpaired, two-tailed Student’s t test).
fibrosarcomas were treated as in (A)–(D) and CD11b+ TILs were purified by
ecific antibodies (gating exemplified on the left). Sorted cells were cocultured
d supernatants were assessed for interferon-g (IFN-g, middle) and interleukin-2
sponding gate. Quantitative data are represented as means ± SEM; **p < 0.01,
treated (left) or DX-treated (right) tumors were inoculated in the footpad of naive
205 tumor cells. Tumor incidence and growth were then routinely assessed.
ving ten mice/group is depicted. **p < 0.01, ***p < 0.001 (log-rank test).
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Figure 4. Chemotherapy-Induced and ATP-Dependent Enrichment of Granulocyte Monocyte Progenitors in Tumor-Infiltrating Leucocytes
C57BL/6micebearingwild-type (WT)orCD39-expressing (CD39)MCA205fibrosarcomaswere treatedwithdoxorubicin (DX) i.t.orwithanequivalent volumeofPBS.
(A) 24 hr later, tumors were harvested and the expression of hematopoietic progenitor markers (CD34, c-Kit, Sca-1, and CD16/32) on CD45+CD3B220CD11b+
(Ly6Chi, Ly6Clo, or Ly6G+) tumor-infiltrating cells was analyzed by flow cytometry. Numbers indicate the percentage of cells found within the corresponding gate.
Please note that the CD34+c-Kit+Sca-1CD16/32+ phenotype marks commonmyeloid progenitors (CMPs) as well as granulocyte-monocyte progenitor (GMPs).
(B–F) Alternatively, tumors were harvested at the indicated time points (24 hr, where not indicated), and CD11b+Ly6Chi and CD11b+Ly6G+ tumor-infiltrating cells
were characterized by RT-PCR for the expression of transcriptional regulators (the monocytic factors PU.1 and Nab-2, the granulopoietic factor Gfi-1, and the
erythroid and megakaryocytic factors Gata-1 and Gfi1b) (B) or used in clonogenic assays in methylcellulose-based medium (C–F).
(legend continued on next page)
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Antigen-Presenting Cells in Anthracycline Therapyrecruitment of TILs to the tumor bed. In contrast, pharmacolog-
ical inhibition of purinergic receptors with suramin was more
efficient in blocking the chemotherapy-elicited infiltration of
tumors by DCs and granulocytes than that by macrophages.
Lymphadenectomy failed to affect the therapeutic response of
mice to anthracyclines, nor did the neutralization or blockade of
the LTb-LTbR and IL-7-IL-7R systems. These findings suggest
that TILs accumulating in the tumor upon chemotherapy can
mediate anticancer immune responses without the need to
migrate into lymph nodes nor to form tertiary lymphoid struc-
tures. It appears therefore plausible that CD11c+CD11b+Ly6Chi
TILs may efficiently process and present tumor cell antigens
(which they readily take up in vivo, as indicated by the transfer
of cancer cell-derived EGFP into their cytoplasm) locally, within
the tumor bed.
ATP can be released fromdying cells in response to physiolog-
ical cell death inducers (such as glucocorticoids acting on thymo-
cytes) (Chekeni et al., 2010; Elliott et al., 2009) or therapeutic
interventions including radiotherapy and chemotherapy (Martins
et al., 2009).Within tissues, theconcentrationof extracellular ATP
([ATP]e) in the proximity of stressed and dying cells is believed to
decrease along a steep gradient, owing to the presence of ecto-
ATPases that are expressed by a variety of cell types (including
FOXP3+ Treg and Th17 cells) (Borsellino et al., 2007; Chalmin
et al., 2012; Schreiber et al., 2011) aswell as of soluble, plasmatic
ATPases (Yegutkin et al., 2003). Such a pattern of [ATP]e may
facilitate themigration ofmyeloid cells toward dying cells. Our re-
sults are compatible with the notion that ATP acts as a specific
chemotactic (and perhaps chemotropic) signal that emanates
from dying cells. Indeed, CD11c+CD11b+Ly6Chi TILs, as well as
othermyeloid populations, were foundwithin nests of dying cells,
and—more precisely—in close proximity of cells that manifested
apoptotic caspase-3 activation (Kroemer et al., 2007). Moreover,
ATP may affect the differentiation of pluripotent myeloid cell
populations recruited into the tumor bed, in linewith its previously
reported capacity to promote the differentiation of hematopoietic
stem cells (Barbosa et al., 2011) and the cardinal importance of
purinergic receptors for DC differentiation in vitro (Wilkin et al.,
2001). CD11b+Ly6ChiLy6G TILs were found to contain a subset
of GMPs that became particularly enriched after chemotherapy,
provided that CD39 was not expressed by cancer cells. In the
absence of dying tumor cell-derived ATP, CD11b+Ly6ChiLy6G
TILs (as well as their bone marrow-derived counterparts) prefer-
entially differentiated into granulocytes. The capacity of anthra-
cycline-treated cancer cells to skew the differentiation of
CD11b+Ly6ChiLy6G TILs toward an inflammatory DC-like
phenotype depended on ATP and purinergic receptors, both
in vitro and in vivo. Altogether, these observations suggest a
dual role for ATP in the tumor microenvironment. First, ATP
would be essential for the recruitment of myeloid cells into the
proximity of dying cells and, second, ATP would facilitate the
local differentiation and maintenance of cells with the phenotype
of inflammatory DCs.(B and C) Quantitative data (means ± SEM); **p < 0.01, ***p < 0.001 (unpaired, tw
(D–F) Morphology of colonies generated from CD11b+Ly6Chi TILs (scale bar rep
nofluorescence microscopy upon Hoechst 33342 counterstaining (scale bar repr
from these cells (scale bar represents 5 mm, original magnification 4003) (F).
See also Figure S4.Multiple distinct DC subsets have been involved in anticancer
immunosurveillance (Palucka and Banchereau, 2012), and
advanced tumors can actually convert tumor-infiltrating DCs
into immunosuppressive cells (Gabrilovich et al., 2012). In the
specific context of anthracycline-based chemotherapy, howev-
er, only inflammatory DC-like CD11c+CD11b+Ly6Chi cells were
found to be essential for optimal immune system-mediated anti-
cancer responses. Indeed, several distinct manipulations sup-
pressing the accumulation of such inflammatory DC-like cells
in the tumor bed also abolished the antitumor activity of anthra-
cycline-based chemotherapy. In contrast, the depletion of pDCs,
neutrophils, or macrophages with antibodies targeting PDCA-1
and Ly6G or clodronate-containing liposomes, as well as the
elimination of Batf3-dependent DCs, had no major impact on
chemotherapeutic responses. Intriguingly, inflammatory DCs,
which are particularly important for chemotherapy-elicited im-
munosurveillance, can differentiate in response to HMGB1
(Han et al., 2008), suggesting that HMGB1 released from dying
cancer cells may further contribute to the maturation and/or
differentiation of TILs toward such phenotype. Irrespective of
these possibilities, our results unravel the essential contribution
of one particular DC-like subset, namely the CD11c+CD11b+
Ly6Chi population, to the therapeutic anticancer immune
response elicited by anthracyclines.
The question as towhether chemotherapy elicits de novo T cell
priming and/or reactivates local effector and/or memory T cells
remains elusive. As outlined by De Visser and colleagues (Ciam-
pricotti et al., 2012), oncogene-addicted nonimmunogenic
breast tumors fail to prime a significant T cell response when
they are treated with anthracyclines. However, we speculate
that chemotherapy-induced immunogenic cell deathmay at least
reboot antigen-specific T cell responses that have been initiated
prior to chemotherapy. Our findings indicate that (1) draining
lymph nodes are dispensable for the immune system-mediated
antitumor effects of anthracyclines, (2) inflammatory DCs accu-
mulate within neoplastic lesions in response to anthracyclines,
and these cells function as efficient APCs when extracted from
tumor beds, and (3) no significant CD8+ T cell (OT-I) priming
against the immunodominant epitopes of OVA is detectable in
the spleen and lungs by day 7 after chemotherapy (data not
shown), although such response occurs within the tumor. In line
with these notions, pegylated IL-10-based therapy has been
shown to reactivate intratumoral cancer-specific cytotoxic
CD8+ TILs, to restore the in situ expression of Th1 cytokines,
granzymes, and antigen-presentation molecules, and to culmi-
nate in the control of tumor growth, even in the absence of drain-
ing lymph nodes (Mumm et al., 2011). However, our data do not
formally exclude the possibility that antigen presentation may
take place at extratumoral sites, such as the bone marrow, to
which tumor antigens may be transported by neutrophils (Duffy
et al., 2012). Irrespective of this partially unresolved issue, we
show here that anthracyclines promote a crucial ATP-dependent
pathway whereby the intratumoral accumulation of GMPs ando-tailed Student’s t test).
resents 50 mm) (D), Ki-67+ dots in the nucleus of cells, as assessed by immu-
esents 10 mm) (E), and May-Gru¨nwald-Giemsa staining of a cytospin prepared
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Figure 5. Chemotherapy-Induced and ATP-Dependent Differentiation of CD11b+Ly6Chi Tumor-Infiltrating Leucocytes into Inflammatory
DC-like Cells
(A–C) CD11b+Ly6Chi cells purified from doxorubicin (DX)-treated tumors from C57BL/6 CD45.2 mice were injected into MCA205 tumors implanted in C57BL/6
CD45.1 mice that had been pretreated with DX i.t. or with an equivalent volume of PBS. After 48 hr, tumors were collected and the phenotype of transferred
CD45.2+ cells was analyzed by flow cytometry.
(A) Representative dot plots (numbers indicate the percentage of cells found within the corresponding gate).
(B and C) Quantitative data on the percentage of recovered CD45.2+ cells (B) and on their differentiation into CD11b+Ly6C+Ly6G, CD11b+Ly6G+, or
CD11c+MHC-II+ cells (C) (means ± SEM).
(D–F) CD11b+Ly6Chi or Ly6G+ cells sorted from MCA205 fibrosarcomas treated with DX were labeled with CFSE and inoculated into wild-type (WT) or CD39-
expressing (CD39) MCA205 fibrosarcomas that had been pretreated 48 hr earlier with mitoxantrone (MTX) i.p. or with an equivalent volume of PBS. 48 hr later,
tumors from recipient mice were harvested and processed for immunofluorescencemicroscopy-assisted determinations. Representative images are depicted in
(legend continued on next page)
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Figure 6. The Therapeutic Efficacy of An-
thracyclines Relies on CD11b+ Myeloid
DCs but Neither on Plasmacytoid DCs nor
on Batf3-Dependent DCs
(A) CD11c-DTR/GFP mice bearing wild-type (WT)
MCA205 fibrosarcomas were treated with mitox-
antrone (MTX) i.p., combined with either PDCA-1-
specific or isotype control antibodies (IgGs). Nine
days later, the percentage of CD11c+CD11b
GFP+ tumor-infiltrating cells was determined by
immunofluorescence microscopy. Quantitative
data are reported as means ± SEM; ns, nonsig-
nificant (unpaired, two-tailed Student’s t test).
(B and C) C57BL/6 mice were inoculated with WT
MCA205 fibrosarcoma (B) or EL-4 lymphoma (C)
cells (day7) and, on day 0, they were treated with
doxorubicin (DX) i.t. (B) or oxaliplatin (OX) i.p. (C),
combinedwith either PDCA-1-targeting antibodies
or isotype control IgGson days1, 1, and 2. Tumor
growth was routinely assessed throughout the
experiment (n = 5–8mice/group). Quantitative data
are reported as means ± SEM; ns, nonsignificant,
**p < 0.01 (Mann-Whitney U test).
(D) WT or Batf3/ mice bearing F244 sarcomas
were treated with MTX i.p. or an equivalent volume
of PBS. Two days later, tumors were harvested
and processed for the immunofluorescence
microscopy-assisted detection of CD11b+CD11c+
DCs within the tumor bed (n = 4–5 mice/
group). Quantitative data are reported as means ±
SEM; ns, nonsignificant (unpaired, two-tailed Stu-
dent’s t test).
(E) WT or Batf3/ 129/Sv mice were inoculated with WT F244 sarcoma cells (day 7) and, on day 0, they were treated with DX i.t. or an equivalent volume of
PBS. Tumor growthwas routinely assessed throughout the experiment (n = 5–8mice/group). Quantitative data are reported asmeans± SEM; ns, nonsignificant, **p <
0.01 (Mann-Whitney U test).
(F and G) CD11c-DTR/GFP mice bearing WTMCA205 fibrosarcomas were treated with MTX i.p., DX i.t., or with an equivalent volume of PBS, combined with either
CD11b-specific antibodies or isotype control IgGs, which were administered 1 day before and on the same day as chemotherapy. 20 and 38 hr later, blood (F) and
tumor (G) samples were collected and analyzed by flow cytometry and immunofluorescence microscopy, respectively, for the abundance of CD11b+
Ly6Chi and CD11c+CD11bGFP+ cells, respectively. Quantitative data are reported as means ± SEM; **p < 0.01, ***p < 0.001 (unpaired, two-tailed Student’s t test).
(H–K)C57BL/6 (Hand I), 129/Sv (J), orBALB/c (K)micewere inoculatedwithWTMCA205 (H), AT3 (I), F244 (J), andH2N100 (K) cells (day=7) and, onday0, theywere
treated DX i.t. or an equivalent volume of PBS, combined with either CD11b-specific antibodies or isotype control IgGs (n > 5 mice/group). Quantitative data are
reported as means ± SEM; ns, nonsignificant, **p < 0.01, ***p < 0.001 (Log-rank Mann-Whitney U test).
See also Figure S6.
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of inflammatory DCs and the activation of T cells against cancer.EXPERIMENTAL PROCEDURES
Tumor Chemotherapy Models
For the establishment of syngenic solid tumors, CB57BL/6 mice received EL-4,
AT3, WT MCA205, or OVA-expressing MCA205 cells, BALB/c mice were inocu-
lated with H2N100, WT CT26, or MyrPalm-mEGFP-expressing CT26 cells, and
WT or Batf3/ 129/Sv mice were engrafted with F244 cells. Tumor growth was
then monitored routinely by means of a caliper, and when the tumor surface(D) (scale bars represent 10 mm), and quantitative data (means ± SEM, n = 2 ind
CD11c+ and CD86+ cells) and (F) (number of CFSE+ cells/tumor).
(G–K) WT and CD39 MCA205 tumor cells were treated with PBS or 25 mM DX for
assay (G) or the coculture with bone marrow-derived (BM) Ly6ChiLy6G cells for 5
with 10 mM 4,40-diisothiocyano-2,20-stilbenedisulfonic acid (DiDS), 500 mM oxid
(IL-1RA), or 20 mg/ml etanercept (H–K). (H) and (I) depict dot plots representative o
lineage, and toward a DC-like phenotype (CD11c+MHCII+), respectively. Numbers
summarize quantitative data (means ± SEM) on the percentage of monocy
(CD11c+MHCII+) (K) cells obtained.
**p < 0.01, ***p < 0.001 (unpaired, two-tailed Student’s t test). See also Figure Sreached 25–45 mm2 (day 0), mice received either DX, MTX, oxaliplatin, or equiv-
alent volumes of solvent. When appropriate, mice received intravenous suramin
or an equivalent volume of solvent, on the same day of chemotherapy. Alterna-
tively, mice received on days 1, 0, and weekly thereafter until the end of the
experiment CD11b-, PDCA-1-, or Ly6G-targeting antibodies. In some protocols,
tumor-bearing mice received on day1, 1, and twice weekly thereafter until the
end of the experiment IL-7- or IL-7R-specific antibodies or LTbR-Fc fusion pro-
teins (kindly provided by Y.-X. Fu, University of Chicago). All experiments were
performed inaccordancewith theFederationofEuropeanLaboratoryAnimalSci-
enceAssociation (FELASA)guidelinesandwereapprovedeitherby the IGREthics
Committee (CEEA IRCIV/IGR no. 26, registered with the French Ministry of
Research) or by thePeterMacCallumAnimal ExperimentationEthicsCommittee.ependent experiments with 3–5 mice/group) are reported in (E) (percentage of
20 hr, followed by the quantification of extracellular ATP by a luciferase-based
days in the presence of 5 ng/ml GM-CSF and 5 ng/ml IL-4, alone or combined
ized ATP (oATP), 2 mM suramin, 20 mg/ml interleukin-1 receptor antagonist
f the commitment toward the monocytic (Ly6C+Ly6G) or granulocytic (Ly6G+)
indicate the percentage of cells foundwithin the corresponding gate. (J) and (K)
tic (CD11b+Ly6ChiLy6G) (J), granulocytic (CD11b+Ly6G+) (J), and DC-like
5.
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For lymph node removal, mice were anesthetized under continuous isoflurane
flow and subjected to skin decontamination with 10% povidone-iodine (com-
mercial Betadine solution). Thereafter, a narrow incision (3mm)wasmade, and
the inguinal lymph node was removed with dissecting forceps. Finally, the inci-
sion was closed with sterile skin closure clips. Sham-operated mice (without
lymph node resection) were treated similarly, and the duration of surgery
was standardized between the two groups. Placing mice on a heater plate
set at 37C until awakening facilitated recovery.
Colony-Forming Assays
Myeloid subpopulations sorted from tumors were resuspended in MethoCult
GF M3434 medium (StemCell Technologies) and 1 ml cell suspension was
dispensed into 35 mm vented Petri dishes (Greiner Bio-One) when bubbles
dissipated. Cultures were then incubated for 7–14 days in standard conditions
in the presence of sterile water to preserve humidity.
ATP Quantification
ATP in culture supernatants was quantified by means of the luciferin-based
ENLITEN ATP Assay Kit (Promega), as per manufacturer’s instructions, on a
Fluostar multiwell plate reader (BMG Labtech).
Statistical Analyses
Unless otherwise indicated, results are expressed asmeans±SEMof n= 3par-
allel assessments. All experimentswere repeated at least twice, yielding similar
results. Normal distributions were compared by unpaired, two-tailed Student’s
t tests, and tumor growth curves were compared by the Mann-Whitney U test.
Kaplan-Meier survival curves were analyzed with the log-rank test. Statistical
analyseswereperformedbymeansof the softwarePrism5 (GraphPad) orExcel
2007 (Microsoft). p values < 0.05 were considered as statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.immuni.2013.03.003.
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